APO Research
Talk to an analyst

APO RESEARCH · REPORT

Gonadotropin-releasing Hormone Agonist Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Gonadotropin-releasing Hormone Agonist Drugs Market Outlook and Growth Opportunities 2026

2 January 2026197 pages

Choose your research edition.

Industry ResearchGonadotropin-releasing Hormone Agonist Drugs Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Gonadotropin-releasing Hormone Agonist Drugs Industry Growth and Trends Forecast to 203294 pages · $3,450 USDMarket StructureGlobal Gonadotropin-releasing Hormone Agonist Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gonadotropin-releasing Hormone Agonist Drugs Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Gonadotropin-releasing Hormone Agonist Drugs Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Gonadotropin-releasing Hormone Agonist Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Gonadotropin-releasing Hormone Agonist Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Gonadotropin-releasing Hormone Agonist Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Gonadotropin-releasing Hormone Agonist Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Gonadotropin-releasing Hormone Agonist Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Gonadotropin-releasing Hormone Agonist Drugs market include Endo, Ferring, Ipsen, LIVZON, TerSera Therapeutics, AstraZeneca, AbbVie, Sanofi and Takeda, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Gonadotropin-releasing Hormone Agonist Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Gonadotropin-releasing Hormone Agonist Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Gonadotropin-releasing Hormone Agonist Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Gonadotropin-releasing Hormone Agonist Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Gonadotropin-releasing Hormone Agonist Drugs Segment by Company

Endo

Ferring

Ipsen

LIVZON

TerSera Therapeutics

AstraZeneca

AbbVie

Sanofi

Takeda

Gonadotropin-releasing Hormone Agonist Drugs Segment by Type

Histrelin

Taltirelin

Leuprorelin

Goserelin

Other

Gonadotropin-releasing Hormone Agonist Drugs Segment by Application

Hospital

Pharmacy

Other

Gonadotropin-releasing Hormone Agonist Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Gonadotropin-releasing Hormone Agonist Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Gonadotropin-releasing Hormone Agonist Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Gonadotropin-releasing Hormone Agonist Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Gonadotropin-releasing Hormone Agonist Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gonadotropin-releasing Hormone Agonist Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gonadotropin-releasing Hormone Agonist Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gonadotropin-releasing Hormone Agonist Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Gonadotropin-releasing Hormone Agonist Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Gonadotropin-releasing Hormone Agonist Drugs industry.

Chapter 3: Detailed analysis of Gonadotropin-releasing Hormone Agonist Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Gonadotropin-releasing Hormone Agonist Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Gonadotropin-releasing Hormone Agonist Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Gonadotropin-releasing Hormone Agonist Drugs Industry Trends Table 2. Gonadotropin-releasing Hormone Agonist Drugs Industry Drivers Table 3. Gonadotropin-releasing Hormone Agonist Drugs Industry Opportunities and Challenges Table 4. Gonadotropin-releasing Hormone Agonist Drugs Industry Restraints Table 5. Global Gonadotropin-releasing Hormone Agonist Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Gonadotropin-releasing Hormone Agonist Drugs Revenue Share by Company (2021-2026) Table 7. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Gonadotropin-releasing Hormone Agonist Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Gonadotropin-releasing Hormone Agonist Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Gonadotropin-releasing Hormone Agonist Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Gonadotropin-releasing Hormone Agonist Drugs Company, Product Type & Application Table 13. Global Gonadotropin-releasing Hormone Agonist Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Gonadotropin-releasing Hormone Agonist Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Histrelin Table 18. Significant Companies of Taltirelin Table 19. Significant Companies of Leuprorelin Table 20. Significant Companies of Goserelin Table 21. Significant Companies of Other Table 22. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Volume by Type (2021-2026) & (K Units) Table 24. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Volume by Type (2027-2032) & (K Units) Table 25. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Volume Share by Type (2021-2026) Table 26. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Volume Share by Type (2027-2032) Table 27. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type (2021-2026) Table 31. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Hospital Table 33. Significant Companies of Pharmacy Table 34. Significant Companies of Other Table 35. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Volume by Application (2021-2026) & (K Units) Table 37. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Volume by Application (2027-2032) & (K Units) Table 38. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Volume Share by Application (2021-2026) Table 39. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Volume Share by Application (2027-2032) Table 40. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application (2021-2026) Table 44. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application (2027-2032) Table 45. Global Gonadotropin-releasing Hormone Agonist Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Gonadotropin-releasing Hormone Agonist Drugs Sales by Region (2021-2026) & (K Units) Table 47. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Market Share by Region (2021-2026) Table 48. Global Gonadotropin-releasing Hormone Agonist Drugs Sales by Region (2027-2032) & (K Units) Table 49. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Market Share by Region (2027-2032) Table 50. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Region (2021-2026) Table 53. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Region (2027-2032) Table 55. Global Gonadotropin-releasing Hormone Agonist Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global Gonadotropin-releasing Hormone Agonist Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global Gonadotropin-releasing Hormone Agonist Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Gonadotropin-releasing Hormone Agonist Drugs Sales by Country (2021-2026) & (K Units) Table 60. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Market Share by Country (2021-2026) Table 61. Global Gonadotropin-releasing Hormone Agonist Drugs Sales by Country (2027-2032) & (K Units) Table 62. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Market Share by Country (2027-2032) Table 63. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Value Market Share by Country (2021-2026) Table 65. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Value Market Share by Country (2027-2032) Table 67. Endo Company Information Table 68. Endo Business Overview Table 69. Endo Gonadotropin-releasing Hormone Agonist Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Endo Gonadotropin-releasing Hormone Agonist Drugs Product Portfolio Table 71. Endo Recent Development Table 72. Ferring Company Information Table 73. Ferring Business Overview Table 74. Ferring Gonadotropin-releasing Hormone Agonist Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Ferring Gonadotropin-releasing Hormone Agonist Drugs Product Portfolio Table 76. Ferring Recent Development Table 77. Ipsen Company Information Table 78. Ipsen Business Overview Table 79. Ipsen Gonadotropin-releasing Hormone Agonist Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Ipsen Gonadotropin-releasing Hormone Agonist Drugs Product Portfolio Table 81. Ipsen Recent Development Table 82. LIVZON Company Information Table 83. LIVZON Business Overview Table 84. LIVZON Gonadotropin-releasing Hormone Agonist Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. LIVZON Gonadotropin-releasing Hormone Agonist Drugs Product Portfolio Table 86. LIVZON Recent Development Table 87. TerSera Therapeutics Company Information Table 88. TerSera Therapeutics Business Overview Table 89. TerSera Therapeutics Gonadotropin-releasing Hormone Agonist Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. TerSera Therapeutics Gonadotropin-releasing Hormone Agonist Drugs Product Portfolio Table 91. TerSera Therapeutics Recent Development Table 92. AstraZeneca Company Information Table 93. AstraZeneca Business Overview Table 94. AstraZeneca Gonadotropin-releasing Hormone Agonist Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. AstraZeneca Gonadotropin-releasing Hormone Agonist Drugs Product Portfolio Table 96. AstraZeneca Recent Development Table 97. AbbVie Company Information Table 98. AbbVie Business Overview Table 99. AbbVie Gonadotropin-releasing Hormone Agonist Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. AbbVie Gonadotropin-releasing Hormone Agonist Drugs Product Portfolio Table 101. AbbVie Recent Development Table 102. Sanofi Company Information Table 103. Sanofi Business Overview Table 104. Sanofi Gonadotropin-releasing Hormone Agonist Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Sanofi Gonadotropin-releasing Hormone Agonist Drugs Product Portfolio Table 106. Sanofi Recent Development Table 107. Takeda Company Information Table 108. Takeda Business Overview Table 109. Takeda Gonadotropin-releasing Hormone Agonist Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Takeda Gonadotropin-releasing Hormone Agonist Drugs Product Portfolio Table 111. Takeda Recent Development Table 112. Key Raw Materials Table 113. Raw Materials Key Suppliers Table 114. Gonadotropin-releasing Hormone Agonist Drugs Distributors List Table 115. Gonadotropin-releasing Hormone Agonist Drugs Customers List Table 116. Research Programs/Design for This Report Table 117. Authors List of This Report Table 118. Secondary Sources Table 119. Primary Sources List of Figures Figure 1. Gonadotropin-releasing Hormone Agonist Drugs Product Image Figure 2. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Gonadotropin-releasing Hormone Agonist Drugs Sales (2021-2032) & (K Units) Figure 5. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Gonadotropin-releasing Hormone Agonist Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Histrelin Image Figure 10. Taltirelin Image Figure 11. Leuprorelin Image Figure 12. Goserelin Image Figure 13. Other Image Figure 14. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Volume Share by Type (2021-2032) Figure 17. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type (2021-2032) Figure 20. Hospital Image Figure 21. Pharmacy Image Figure 22. Other Image Figure 23. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Volume Share by Application (2021-2032) Figure 26. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application (2021-2032) Figure 29. Global Gonadotropin-releasing Hormone Agonist Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 30. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Gonadotropin-releasing Hormone Agonist Drugs Sales Value (2021-2032) & (US$ Million) Figure 34. North America Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Gonadotropin-releasing Hormone Agonist Drugs Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Gonadotropin-releasing Hormone Agonist Drugs Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Gonadotropin-releasing Hormone Agonist Drugs Sales Value (2021-2032) & (US$ Million) Figure 40. South America Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Gonadotropin-releasing Hormone Agonist Drugs Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Gonadotropin-releasing Hormone Agonist Drugs Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Gonadotropin-releasing Hormone Agonist Drugs Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Histrelin
  • Taltirelin
  • Leuprorelin
  • Goserelin
  • Other
Applications
  • Hospital
  • Pharmacy
  • Other
Companies covered
  • Endo
  • Ferring
  • Ipsen
  • LIVZON
  • TerSera Therapeutics
  • AstraZeneca
  • AbbVie
  • Sanofi
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Gonadotropin-releasing Hormone Agonist Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Gonadotropin-releasing Hormone Agonist Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Gonadotropin-releasing Hormone Agonist Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Gonadotropin-releasing Hormone Agonist Drugs Market Dynamics
  1. 2.1 Gonadotropin-releasing Hormone Agonist Drugs Industry Trends
  2. 2.2 Gonadotropin-releasing Hormone Agonist Drugs Industry Drivers
  3. 2.3 Gonadotropin-releasing Hormone Agonist Drugs Industry Opportunities and Challenges
  4. 2.4 Gonadotropin-releasing Hormone Agonist Drugs Industry Restraints
3 Gonadotropin-releasing Hormone Agonist Drugs Market by Company
  1. 3.1 Global Gonadotropin-releasing Hormone Agonist Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Gonadotropin-releasing Hormone Agonist Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Gonadotropin-releasing Hormone Agonist Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Gonadotropin-releasing Hormone Agonist Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Gonadotropin-releasing Hormone Agonist Drugs Company Ranking (2024-2026)
  6. 3.6 Global Gonadotropin-releasing Hormone Agonist Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Gonadotropin-releasing Hormone Agonist Drugs Company Product Type and Application
  8. 3.8 Global Gonadotropin-releasing Hormone Agonist Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Gonadotropin-releasing Hormone Agonist Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Gonadotropin-releasing Hormone Agonist Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Gonadotropin-releasing Hormone Agonist Drugs Market by Type
  1. 4.1 Gonadotropin-releasing Hormone Agonist Drugs Type Introduction
  2. 4.1.1 Histrelin
  3. 4.1.2 Taltirelin
  4. 4.1.3 Leuprorelin
  5. 4.1.4 Goserelin
  6. 4.1.5 Other
  7. 4.2 Global Gonadotropin-releasing Hormone Agonist Drugs Sales Volume by Type
  8. 4.2.1 Global Gonadotropin-releasing Hormone Agonist Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Gonadotropin-releasing Hormone Agonist Drugs Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Gonadotropin-releasing Hormone Agonist Drugs Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Gonadotropin-releasing Hormone Agonist Drugs Sales Value by Type
  12. 4.3.1 Global Gonadotropin-releasing Hormone Agonist Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Gonadotropin-releasing Hormone Agonist Drugs Sales Value by Type (2021-2032)
  14. 4.3.3 Global Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type (2021-2032)
5 Gonadotropin-releasing Hormone Agonist Drugs Market by Application
  1. 5.1 Gonadotropin-releasing Hormone Agonist Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Gonadotropin-releasing Hormone Agonist Drugs Sales Volume by Application
  6. 5.2.1 Global Gonadotropin-releasing Hormone Agonist Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Gonadotropin-releasing Hormone Agonist Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Gonadotropin-releasing Hormone Agonist Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Gonadotropin-releasing Hormone Agonist Drugs Sales Value by Application
  10. 5.3.1 Global Gonadotropin-releasing Hormone Agonist Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Gonadotropin-releasing Hormone Agonist Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application (2021-2032)
6 Gonadotropin-releasing Hormone Agonist Drugs Regional Sales and Value Analysis
  1. 6.1 Global Gonadotropin-releasing Hormone Agonist Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Gonadotropin-releasing Hormone Agonist Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Gonadotropin-releasing Hormone Agonist Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Gonadotropin-releasing Hormone Agonist Drugs Sales by Region (2027-2032)
  5. 6.3 Global Gonadotropin-releasing Hormone Agonist Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Gonadotropin-releasing Hormone Agonist Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Gonadotropin-releasing Hormone Agonist Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Gonadotropin-releasing Hormone Agonist Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Gonadotropin-releasing Hormone Agonist Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Gonadotropin-releasing Hormone Agonist Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Gonadotropin-releasing Hormone Agonist Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Gonadotropin-releasing Hormone Agonist Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Gonadotropin-releasing Hormone Agonist Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Gonadotropin-releasing Hormone Agonist Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Country, 2025 VS 2032
7 Gonadotropin-releasing Hormone Agonist Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Gonadotropin-releasing Hormone Agonist Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Gonadotropin-releasing Hormone Agonist Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Gonadotropin-releasing Hormone Agonist Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Gonadotropin-releasing Hormone Agonist Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Gonadotropin-releasing Hormone Agonist Drugs Sales by Country (2027-2032)
  6. 7.4 Global Gonadotropin-releasing Hormone Agonist Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Gonadotropin-releasing Hormone Agonist Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Gonadotropin-releasing Hormone Agonist Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Gonadotropin-releasing Hormone Agonist Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Gonadotropin-releasing Hormone Agonist Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Endo
  2. 8.1.1 Endo Company Information
  3. 8.1.2 Endo Business Overview
  4. 8.1.3 Endo Gonadotropin-releasing Hormone Agonist Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Endo Gonadotropin-releasing Hormone Agonist Drugs Product Portfolio
  6. 8.1.5 Endo Recent Developments
  7. 8.2 Ferring
  8. 8.2.1 Ferring Company Information
  9. 8.2.2 Ferring Business Overview
  10. 8.2.3 Ferring Gonadotropin-releasing Hormone Agonist Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Ferring Gonadotropin-releasing Hormone Agonist Drugs Product Portfolio
  12. 8.2.5 Ferring Recent Developments
  13. 8.3 Ipsen
  14. 8.3.1 Ipsen Company Information
  15. 8.3.2 Ipsen Business Overview
  16. 8.3.3 Ipsen Gonadotropin-releasing Hormone Agonist Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Ipsen Gonadotropin-releasing Hormone Agonist Drugs Product Portfolio
  18. 8.3.5 Ipsen Recent Developments
  19. 8.4 LIVZON
  20. 8.4.1 LIVZON Company Information
  21. 8.4.2 LIVZON Business Overview
  22. 8.4.3 LIVZON Gonadotropin-releasing Hormone Agonist Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 LIVZON Gonadotropin-releasing Hormone Agonist Drugs Product Portfolio
  24. 8.4.5 LIVZON Recent Developments
  25. 8.5 TerSera Therapeutics
  26. 8.5.1 TerSera Therapeutics Company Information
  27. 8.5.2 TerSera Therapeutics Business Overview
  28. 8.5.3 TerSera Therapeutics Gonadotropin-releasing Hormone Agonist Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 TerSera Therapeutics Gonadotropin-releasing Hormone Agonist Drugs Product Portfolio
  30. 8.5.5 TerSera Therapeutics Recent Developments
  31. 8.6 AstraZeneca
  32. 8.6.1 AstraZeneca Company Information
  33. 8.6.2 AstraZeneca Business Overview
  34. 8.6.3 AstraZeneca Gonadotropin-releasing Hormone Agonist Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 AstraZeneca Gonadotropin-releasing Hormone Agonist Drugs Product Portfolio
  36. 8.6.5 AstraZeneca Recent Developments
  37. 8.7 AbbVie
  38. 8.7.1 AbbVie Company Information
  39. 8.7.2 AbbVie Business Overview
  40. 8.7.3 AbbVie Gonadotropin-releasing Hormone Agonist Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 AbbVie Gonadotropin-releasing Hormone Agonist Drugs Product Portfolio
  42. 8.7.5 AbbVie Recent Developments
  43. 8.8 Sanofi
  44. 8.8.1 Sanofi Company Information
  45. 8.8.2 Sanofi Business Overview
  46. 8.8.3 Sanofi Gonadotropin-releasing Hormone Agonist Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Sanofi Gonadotropin-releasing Hormone Agonist Drugs Product Portfolio
  48. 8.8.5 Sanofi Recent Developments
  49. 8.9 Takeda
  50. 8.9.1 Takeda Company Information
  51. 8.9.2 Takeda Business Overview
  52. 8.9.3 Takeda Gonadotropin-releasing Hormone Agonist Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Takeda Gonadotropin-releasing Hormone Agonist Drugs Product Portfolio
  54. 8.9.5 Takeda Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Gonadotropin-releasing Hormone Agonist Drugs Value Chain Analysis
  2. 9.1.1 Gonadotropin-releasing Hormone Agonist Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Gonadotropin-releasing Hormone Agonist Drugs Sales Mode & Process
  6. 9.2 Gonadotropin-releasing Hormone Agonist Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Gonadotropin-releasing Hormone Agonist Drugs Distributors
  9. 9.2.3 Gonadotropin-releasing Hormone Agonist Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst